Key clinical point: A bispecific anti-CD19, anti-CD20 chimeric antigen receptor (CAR) T cell approach is safe and produced complete responses in the majority of patients with relapsed or refractory non-Hodgkin lymphoma.
Major finding: Eleven of 17 assessable patients had a response to treatment, and of those 11 patients, 9 had complete responses, all of which are ongoing.
Study details: A phase 1 study of 17 patients with relapsed or refractory B-cell non-Hodgkin lymphomas.
Disclosures: Dr. Shah reported disclosures related to Cidara Therapeutics, Exelixis, Geron, Oncosec, Incyte, Jazz Pharmaceuticals, Juno Therapeutics, Kite Pharma, and Miltenyi Biotec.
Shah NN et al. ASCO 2019. Abstract 2510.
This Week's Must Reads
Must Reads in Aggressive Lymphomas
Researchers characterize new subtype of high-grade DLBCL, 3 articles from the Journal of Clinical Oncology